Table 1. Univariate analysis for response to chemotherapy and overall survival by clinical variables.
| Variables | No. of | Response to chemotherapy | Overall survival | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| responders | nonresponders | OR (95% CI) | P | MST | 95% CI | Log-Rank | HR (95% CI) | P | ||
| cases | (CR + PR) | (SD + PD) | (months) | P | ||||||
| Overall | 379 | 180 (47.5)a | 199 (52.5) | 13.2 | 12.5–14.7 | |||||
| Age (years) | ||||||||||
| <65 | 179 | 93 (52.0) | 86 (48.0) | 1.00 | 15.7 | 13.7–17.7 | 1.00 | |||
| ≥65 | 200 | 87 (43.5) | 113 (56.5) | 0.71 (0.48–1.07) | 0.10 | 11.9 | 10.8–13.2 | 0.003 | 1.38 (1.11–1.70) | 0.003 |
| Gender | ||||||||||
| Male | 309 | 153 (49.5) | 156 (50.5) | 1.00 | 12.8 | 11.9–14.3 | 1.00 | |||
| Female | 70 | 27 (38.6) | 43 (61.4) | 0.64 (0.38–1.09) | 0.10 | 16.8 | 12.8–22.6 | 0.02 | 0.73 (0.56–0.96) | 0.02 |
| Smoking status | ||||||||||
| Never | 63 | 27 (42.9) | 36 (57.1) | 1.00 | 19.6 | 13.7–30.4 | 1.00 | |||
| Ever | 316 | 153 (48.4) | 163 (51.6) | 1.25 (0.73–2.16) | 0.42 | 12.8 | 11.7–14.2 | 0.001 | 1.59 (1.20–2.12) | 0.002 |
| Histological type | ||||||||||
| Squamous cell ca. | 184 | 98 (53.3) | 86 (46.7) | 1.00 | 13.2 | 11.7–14.4 | 1.00 | |||
| Adenoca. | 172 | 71 (41.3) | 101 (58.7) | 0.62 (0.41–0.94) | 0.02 | 15.1 | 12.1–17.5 | 0.74 (0.59–0.92) | 0.01 | |
| NSCLC-NOS | 23 | 11 (47.8) | 12 (52.2) | 0.80 (0.34–1.92) | 0.62 | 11.4 | 7.4–12.9 | 0.01 | 1.25 (0.80–1.99) | 0.34 |
| Clinical stage | ||||||||||
| III | 159 | 82 (51.6) | 77 (48.4) | 1.00 | 14.7 | 12.8–17.4 | 1.00 | |||
| IV | 220 | 98 (44.6) | 122 (55.5) | 0.75 (0.50–1.14) | 0.18 | 12.7 | 10.8–14.2 | 0.12 | 1.18 (0.96–1.47) | 0.12 |
| PS ECOG | ||||||||||
| 0–1 | 310 | 149 (48.1) | 161 (51.9) | 1.00 | 14.1 | 12.6–15.7 | 1.00 | |||
| 2 | 69 | 31 (44.9) | 38 (55.1) | 0.88 (0.52–1.49) | 0.64 | 12.6 | 9.7–13.2 | 0.42 | 1.12 (0.85–1.48) | 0.42 |
| Weight loss | ||||||||||
| No | 233 | 116 (49.8) | 117 (50.2) | 1.00 | 14.4 | 12.5–16.6 | 1.00 | |||
| Yes | 146 | 64 (43.8) | 82 (56.2) | 0.79 (0.52–1.19) | 0.26 | 12.9 | 11.6–14.0 | 0.001 | 1.47 (1.18–1.83) | 0.001 |
| 2nd line Chemotherapy | ||||||||||
| No | 132 | 11.0 | 8.1–12.8 | 1.00 | ||||||
| Yes | 247 | 15.1 | 13.2–16.6 | 0.02 | 0.76 (0.61–0.95) | 0.02 | ||||
| Radiation to tumor | ||||||||||
| No | 340 | 12.9 | 11.6–14.3 | 1.00 | ||||||
| Yes | 39 | 18.5 | 14.0–23.9 | 0.19 | 0.80 (0.57–1.12) | 0.19 | ||||
Abbreviation: OR, odds ratio; MST, median survival time; CI, confidence interval; HR, hazard ratio; PS, performance status; ECOG, Eastern Cooperative Oncology Group.
aRow percentage.